Sentences with phrase «as neoantigens»

Blame for treatment failures is usually attributed to so - called «cold» tumors, those that do not attract T - cell infiltration and may lack key T - cell targets — the mutated proteins known as neoantigens.

Cancer cells may contain mutations in genes that code for antigens, producing misshapen or otherwise altered antigens that are known to scientists as neoantigens.

Rather than simply identifying a cancer by location or tissue type, researchers now use advanced molecular profiling tests to characterize tumors, the proteins they express and the novel mutations they develop — known as neoantigens.

Not exact matches

His work indicates that this cell surface marker could serve as a target for a novel brain cancer vaccine or T - cell therapies engineered to recognize and kill tumors carrying that neoantigen.

«Now that we can recognize cells altered by APOBEC3, we could teach tumor neoantigen - based immunotherapies to recognize these cells as well,» Pyeon says.

Algorithms, such as NetMHC, have been developed in recent years, making it feasible to select HLA - binding neoantigen peptides for the vaccine.

The researchers say the results warrant further development of neoantigen vaccines, both alone and in combination with other immunotherapy weapons such as checkpoint inhibitors.

Some cancers may have too many mutations to test as potential neoantigens.

However, identifying neoantigens can still be useful as cancer biomarkers.

In addition, it was increasingly recognized that oncolytic viruses not only were able to directly lyse cancer cells, but they also «freed «tumor specific neoantigens, indirectly acting as a cancer vaccine.

Our immuno - oncology product candidates are being developed in two separate approaches: one that targets specific antigens and / or epitopes (such as CMB305 and in our neoantigen collaboration); and an alternative approach that leverages the endogenous antigens found in the tumor microenvironment via intratumoral immunization (such as G100).

Neoantigens — called so because they are newly formed during cancer development — may represent ideal immunotherapy targets as they are solely expressed on tumor cells.

In addition to conserved antigens, these next - gen ZVex agents will be designed to produce personalized neoantigen - based immunotherapies, as well.

Instead of targeting specific tumor antigens, this approach relies on endogenous antigens (including neoantigens) released during tumor lysis by treatments such as chemotherapy or local radiation.

Designed to target multiple conserved antigens without antigen competition, as well as patient - specific neoantigens, with immunostimulatory molecules